SG3199-Val-Ala-PAB-DataSheet-生命科學(xué)試劑-MedChemExpress

Hotline:400-820-3792Inhibitors?ScreeningLibraries?Proteinswww.MedChemESG3199-Val-Ala-PABCat.No.:HY-101152CASNo.:1595275-61-8分?式:C??H??N?O??分?量:922.03作?靶點(diǎn):Drug-LinkerConjugatesforADC作?通路:Antibody-drugConjugate/ADCRelated儲(chǔ)存?式:-20°C,protectfromlight,storedundernitrogen*Insolvent:-80°C,6months;-20°C,1month(protectfrom

light,storedundernitrogen)溶解性數(shù)據(jù)體外實(shí)驗(yàn)DMSO:130mg/mL(140.99mM;Needultrasonic)MassSolvent1mg5mg10mgConcentration制備儲(chǔ)備液1mM1.0846mL5.4228mL10.8456mL5mM0.2169mL1.0846mL2.1691mL10mM0.1085mL0.5423mL1.0846mL請(qǐng)根據(jù)產(chǎn)品在不同溶劑中的溶解度選擇合適的溶劑配制儲(chǔ)備液；?旦配成溶液，請(qǐng)分裝保存，避免反復(fù)凍融造成的產(chǎn)品失效。儲(chǔ)備液的保存?式和期限：-80°C,6months;-20°C,1month(protectfromlight,storedundernitrogen)。-80°C儲(chǔ)存時(shí)，請(qǐng)?jiān)?個(gè)?內(nèi)使?，-20°C儲(chǔ)存時(shí)，請(qǐng)?jiān)?個(gè)?內(nèi)使?。體內(nèi)實(shí)驗(yàn)請(qǐng)根據(jù)您的實(shí)驗(yàn)動(dòng)物和給藥?式選擇適當(dāng)?shù)娜芙?案。以下溶解?案都請(qǐng)先按照InVitro?式配制澄的儲(chǔ)備液，再依次添加助溶劑：(為保證實(shí)驗(yàn)結(jié)果的可靠性，澄的儲(chǔ)備液可以根據(jù)儲(chǔ)存條件，適當(dāng)保存；體內(nèi)實(shí)驗(yàn)的?作液，建議您現(xiàn)?現(xiàn)配，當(dāng)天使?；以下溶劑前顯?的百分?指該溶劑在您配制終溶液中的體積占?；如在配制過(guò)程中出現(xiàn)沉淀、析出現(xiàn)象，可以通過(guò)加熱和/或超聲的?式助溶)1.請(qǐng)依序添加每種溶劑：10%DMSO>>40%PEG300>>5%Tween-80>>45%salineSolubility:≥3.25mg/mL(3.52mM);Clearsolution2.請(qǐng)依序添加每種溶劑：10%DMSO>>90%cornoilSolubility:≥3.25mg/mL(3.52mM);Clearsolution1/2MasterofBioactiveMolecules—您?邊的抑制劑?師www.MedChemEBIOLOGICALACTIVITY?物活性SG3199-Val-Ala-PABTesirine合成的中間體。Tesirine?種?于抗體偶聯(lián)藥物(ADC)的藥物-linker連接物，能?于多種癌癥的研究。體外研究SG3199-Val-Ala-PABisanintermediateininthesynthesisofTesirine,anantibody-drugconjugatepyrrolobenzodiazepinedimerpayload[1].REFERENCES[1].TiberghienAC,et,al.DesignandSynthesisofTesirine,aClinicalAntibody-DrugConjugatePyrrolobenzodiazepineDimerPayload.ACSMedChemLett.2016May24;7(11):983-987.McePdfHeightCaution:Producthasnotbeenfullyvalidatedformedicalapplications.Forresearchuseonly.Tel:400-820-3792;021